Clinical Investigation of the Bi Flex M Multifocal IOL
Randomised Clinical Investigation of the Bi Flex M Multifocal Intraocular Lens
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age related cataract patients requiring cataract surgery with phacoemulsification.
- Patients requiring primary IOL implantation
- Patients with a potential corrected visual acuity of 20/40 or better on clinical assessment
- Patients with normal anterior segments apart from cataracts
- Subjects with clear intraocular media other than cataract
Exclusion Criteria:
- Preexisting pathology or physiology, which may be aggravated by the implant, or may render the implant ineffective and that could potentially cause future acuity losses to a level of 0.5 or 20/40 or worse in either eye. This includes the following:
- Microphthalmia
- Corneal decompensation or Endothelial Insufficiency
- Pseudo exfoliation
- High myopia
- Pars planitis
- Patient with greater than 1 dioptre of preoperative corneal astigmatism
- Subjects who are expected to require retinal laser treatment
- Previous intraocular and/or corneal surgery
- History of uveitis, glaucoma, proliferative diabetic retinopathy, pseudoexfoliation, macular degeneration that may affect potential best corrected visual acuity of 20/40 or better
- Operative complications of posterior capsular rupture, zonular dehiscence, incomplete continuous curvilinear capsulorhexis, severe iris /corneal trauma and inability to achieve secure placement in the designated location
- Subjects using a systemic medication that is known to cause ocular side effects
- Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days
- Subjects who have only one eye with potentially good vision
- Patients who are not willing to cooperate for the follow up period
- Visual eccentricity of greater than 0.7mm
- Pregnant women
- Patients where it is not possible to take informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bi flex M multifocal intraocular lens
Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
|
Multifocal intraocular lens
|
|
Active Comparator: Bi flex 1.8 monofocal intraocular
Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
|
Standard monofocal intraocular lens
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long Term Monocular Visual Acuity (VA)
Time Frame: Visit 2 [12-18 months]
|
Monocular Visual acuity at 12-18 months assessed at distance intermediate and near both corrected and uncorrected.
Assessed in LogMAR
|
Visit 2 [12-18 months]
|
|
Long Term Binocular Visual Acuity (VA)
Time Frame: Visit 2 [12-18 months]
|
Binocular Visual acuity at 12-18 months assessed at distance intermediate and near both corrected and uncorrected.
Assessed in LogMAR
|
Visit 2 [12-18 months]
|
|
Monocular Visual Acuity (VA)
Time Frame: Visit 1 [3-6 months]
|
Monocular Visual acuity at 3-6 months assessed at distance intermediate and near both corrected and uncorrected.
Assessed in LogMAR
|
Visit 1 [3-6 months]
|
|
Binocular Visual Acuity (VA)
Time Frame: Visit 1 [3-6 months]
|
Binocular Visual acuity at 3-6 months assessed at distance intermediate and near both corrected and uncorrected.
Assessed in LogMAR
|
Visit 1 [3-6 months]
|
|
Defocus Curve Profiles
Time Frame: visit 1 (3-6 months)
|
Visual acuity measurement (assessed in LogMAR) taken with differing levels of optical defocus
|
visit 1 (3-6 months)
|
|
Long Term Defocus Curve Profiles
Time Frame: visit 2 (12-18 months)
|
Assessed as a dioptric range and using the Defocus area metric
|
visit 2 (12-18 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long Term Monocular Pelli-Robson Contrast Sensitivity (CS)
Time Frame: Visit 2 [12-18 months]
|
MonocularContrast sensitivity assessed as a contrast threshold using the Pelli-Robson test
|
Visit 2 [12-18 months]
|
|
Long Term Binocular Pelli-Robson Contrast Sensitivity (CS)
Time Frame: Visit 2 [12-18 month]
|
Binocular Contrast sensitivity assessed as a contrast threshold using the Pelli-Robson test
|
Visit 2 [12-18 month]
|
|
Pelli-Robson Monocular Contrast Sensitivity
Time Frame: Visit 1 [3-6 months]
|
Monocular Contrast sensitivity assessed as a contrast threshold using the Pelli-Robson test
|
Visit 1 [3-6 months]
|
|
Pelli-Robson Binocular Contrast Sensitivity
Time Frame: Visit 1 [3-6 months]
|
Contrast sensitivity assessed as a contrast threshold using the Pelli-Robson test
|
Visit 1 [3-6 months]
|
|
Long Term Contrast Sensitivity CSV-1000
Time Frame: Visit 2 [12-18 months]
|
Binocular Assessment of Contrast Sensitivity at threshold using the Contrast sensitivity vision(CSV) CSV-1000
|
Visit 2 [12-18 months]
|
|
Contrast Sensitivity CSV-1000
Time Frame: Visit 1 [3-6 months]
|
Binocular Assessment of Contrast Sensitivity at threshold using the CSV-1000
|
Visit 1 [3-6 months]
|
|
Long Term Reading Performance
Time Frame: Visit 2 (12-18 months)
|
Assessed as the critical print size and using the reading performance index.
Uses Radner reading chart and logarithmic Radner scale (LogRAD) Lower LogRAD equals smaller print size
|
Visit 2 (12-18 months)
|
|
Reading Performance
Time Frame: visit 1 (3-6 months)
|
Assessed as the critical print size and using the reading performance index Logarithmic Radner scale (LogRAD) Lower LogRAD equals small print size
|
visit 1 (3-6 months)
|
|
Long Term Glare
Time Frame: Visit 2 (12-18 months)
|
Assessed as the glare area size Scale 0 to 100 Higher scores = larger glare area =worse outcome
|
Visit 2 (12-18 months)
|
|
Glare
Time Frame: visit 1 (3-6 months)
|
Assessed as the glare area size Scale 0 to 100 Higher score = larger area = worse outcome
|
visit 1 (3-6 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Phillip J Buckhurst, PhD, Plymouth University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MC001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.